Background: Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent antimitotic agent, monomethyl auristatin E, which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients.
Introduction
Most patients with relapsed epithelial ovarian cancers (OCs) initially respond to platinum-based chemotherapy [1] . However, approximately 25% of patients recur within 6 months following initial platinum chemotherapy, developing 'platinum-resistant' ovarian cancer (PROC) [2] . Eventually, almost all OC patients become platinum resistant [2] , traditionally defined as disease recurrence <6 months since last platinum-based therapy [3] . Single agents approved for PROC have overall response rates from 6.5% to 20.5% and a progression-free survival (PFS) from 2 to 6 months [4] . Thus, there is an urgent need for more effective therapies for the treatment of PROC [5] .
Lifastuzumab vedotin (DNIB0600A) (LIFA) is an antibodydrug conjugate (ADC) [6, 7] that comprises a humanized IgG 1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. ADC formats utilizing MMAE are known to significantly enhance clinical activity compared with the naked antibody [8] . The LIFA drug target, NaPi2b, is a sodium-dependent phosphate transporter and potentially a highly selective clinical target [9, 10] . NaPi2b is expressed in OC, nonsquamous non-small-cell lung cancer, and papillary thyroid cancer. NaPi2b protein is expressed at an immunohistochemistry (IHC) level of 2þ/3þ in 90% of OC. The feasibility of targeting NaPi2b in OC has been demonstrated in the clinic with a radiolabeled antibody (MX35) [9] .
Animal studies have demonstrated that conjugation of MMAE to anti-NaPi2b improved tolerability and widened the therapeutic window [11] . Patients with NaPi2b deficiency are rare and phenotypically present late in life with calcifications in the lungs and seminiferous tubules [12, 13] . A phase I study of LIFA in patients with non-small-cell lung cancer and PROC demonstrated encouraging safety profile and evidence of antitumor activity [14] , with confirmed response rate of 41% in a late line PROC population. The current phase II study of LIFA was undertaken in PROC patients, and included exploratory biomarker studies.
Methods
Study NCT01991210 (ClinicalTrials.gov) was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The primary objective was to evaluate the efficacy of LIFA in comparison to the standard-of-care (SOC) option, pegylated liposomal doxorubicin (PLD), in PROC patients.
Patients
PROC patients 18 years of age with histologically documented advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer that had progressed or relapsed within 6 months of the most recent treatment with a platinum-containing chemotherapy regimen and for whom PLD was considered an appropriate therapy were enrolled. Patients were excluded if they underwent any major surgical procedure or received antitumor therapy within 4 weeks before day 1 (chemotherapy, biologic, experimental, or hormonal therapy), or received palliative radiation within 2 weeks before day 1. Other inclusion and exclusion criteria are included in supplementary materials, available at Annals of Oncology online.
Study design and treatment
This was a randomized, open-label, phase II study, with equal assignment (1 : 1) to each of two arms, LIFA and PLD. Randomization was stratified by platinum-free interval (<3 months versus 3-6 months), the number of prior platinum-containing regimens (<2 versus 2), and the number of regimens for PROC (0 versus [1] [2] 
Criteria for treatment modifications
Study treatment was discontinued for any patient with grade 3 peripheral neuropathy. Patients who experienced treatment-related grade 3/4 toxicity or any grade 2 neuropathy were allowed to delay dosing for up to 2 weeks and resume at 1.8 mg/kg if toxicity resolved (grade 1). Patients were discontinued for persistence of toxicity at 1.8 mg/kg. Patients on the PLD arm who experienced treatment-related toxicities had their PLD dose reduced according to institutional prescribing and labeled dosereduction standards.
Samples
Patient tumor tissue samples (archival or fresh), serum, and plasma were collected at specified time points. Validated enzyme-linked immunosorbent assay (ELISA) assays were used to determine antidrug antibody (ADA) to LIFA, and circulating CA-125 [15] and human epididymis protein 4 (HE4) levels. Pharmacokinetic assays were carried out using validated ELISA and liquid chromatography-tandem mass spectrometry methods. Tissue samples underwent central pathologic review for NaPi2b expression by validated IHC assay (supplementary materials, available at Annals of Oncology online) and quantitative real-time polymerase chain reaction (qRT-PCR) assay [16] .
Assessments
Safety outcome measures included adverse events (AEs), discontinuations from drug dosing due to AEs, incidence of ADA, and changes in vital signs, electrocardiograms, and laboratory values. Patients remained on study treatment until disease progression, unacceptable toxicities, or patient request for withdrawal. Patients underwent an end of treatment assessment no later than 30 days after withdrawal from treatment.
Efficacy outcome measurements included PFS, overall survival (OS), objective response (OR), and duration of objective response (DoR). PFS was defined as the time from the first study treatment (cycle 1, day 1) to the first occurrence of progression or death within 30 days after the last study drug dose. Tumor assessment was carried out every 8 weeks regardless of the treatment cycles. PFS for patients without disease progression or death was censored at the time of the last tumor assessment. OS was defined as the time from the first study treatment (cycle 1, day 1) to date of death from any cause. OR was defined as complete response (CR) or partial response (PR). Tumor response was evaluated according to RECIST v1.1, CA-125, and clinical criteria; CA-125 was evaluated using the Gynecological Cancer InterGroup (GCIG) definition [15, 17] . DoR measured time from the first occurrence of a documented OR until the time of relapse or death from any cause.
Patient-reported outcomes (PROs) assessing disease and treatmentrelated symptoms as well as health-related quality of life (HRQoL) were obtained using the MD Anderson Symptom Inventory-Ovarian Cancer (MDASI-OC) [18] ; three items to assess toxicities of PLD and the twoitem global health status/quality of life (GHS/QOL) scale were obtained from the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core Module 30 (EORTC QLQ-C30). Changes in 10 points on the GHS/QoL have been identified as indicative of a meaningful change [19] . Completion of PROs began on cycle 1, day 1 before the patient being informed of their study drug assignment, and continued weekly until approximately 30 days after the last dose of study treatment. PRO was an exploratory end point and descriptive summaries were planned.
Statistical analysis
Assuming 3.7 months of median PFS time in the PLD arm and approximately 85% of patients to have NaPi2b-high tumors by IHC, 92 patients were required to achieve 80% power to detect a hazard ratio (HR) of 0.45 at two-sided significance level of 5%. At the time of data cutoff, approximately 50 PFS events were anticipated among NaPi2b-high patients; NaPi2b-high patients were predefined as IHC 2þ/3þ with a 50% cutoff for staining. Kaplan-Meier methods were used to estimate the median PFS. Safety analyses included all randomized patients in the two treatment arms who received any amount of treatment.
Results
Between February 2014 and February 2015, 95 patients were randomized (LIFA: n ¼ 47, PLD: n ¼ 48) in 35 sites (supplementary Figure S1 , available at Annals of Oncology online). Ninetythree patients received at least one dose of study drug. At data cutoff (1 July 2015) there were 64 PFS events, 23 OS events, and 22 patients remained on study. All patients were followed for a median time of 6.6 months. Baseline demographics were generally balanced between the two groups ( Table 1) . Primary (PFS) and secondary (OR and OS) efficacy analyses included all 95 randomized patients in the intent-to-treat (ITT) population. All patients were followed to progression; the PFS primary end point was analyzed when approximately 59 investigator-assessed PFS events occurred.
Efficacy
The HR for stratified PFS was 0.78 [95% confidence interval (95% CI), 0.46-1.31; P ¼ 0.34] with a median PFS of 5.3 months for LIFA versus 3.1 months for PLD in the ITT population ( Figure 1 ). The median DoR was 5.5 months for LIFA versus 3.9 months for PLD in the ITT population. In NaPi2b-high patients (IHC 2þ/3þ with a 50% cutoff for staining), the HR for PFS was 0.71 (95% CI, 0.40-1.26; P ¼ 0.24) with a median PFS of 5.3 months with LIFA versus 3.4 months with PLD. The investigator assessed best response rate (RECIST v1.1) was 34% (LIFA: 95% CI, 22% to 49%) versus 15% (PLD: 95% CI, 7% to 28%) in the ITT population (P ¼ 0.03), and 36% (LIFA: 95% CI, 22% to 52%) versus 14% (PLD: 95% CI, 6% to 27%) in the NaPi2b-high group (P ¼ 0.02). In the ITT population, responses included 1 CR and 15 PR on the LIFA arm (n ¼ 47) and 1 CR and 6 PR on the PLD arm (n ¼ 48) (supplementary Figure S2 , available at Annals of Oncology online). NaPi2b-high population, arbitrarily defined as patients with NaPi2b IHC 2þ/3þ, accounted for 93% of ITT, and responses included 1 CR and 14 PR on the LIFA arm (n ¼ 42) and 1 CR and 5 PR on the PLD arm (n ¼ 43).
The global HRQoL status (GHS/QoL) captured as PRO assessments during the course of the clinical study consistently showed no meaningful decline in the LIFA arm (mean change: -3.61 at 9 weeks and -5.36 at 24 weeks) and a clinically meaningful decline (10 point decrease) [19] in the PLD arm (mean change: -11.51 at 9 weeks and -17.59 at 24 weeks). Due to the small sample size, no statistical tests were conducted on the PRO end points.
Safety and disposition
At the time of analysis, 71 patients (77%) had discontinued study treatment [LIFA: n ¼ 33 (72%); PLD: n ¼ 38 (81%)], most commonly for disease progression [LIFA: n ¼ 29 (63%); PLD: n ¼ 31 (66%)]. Number of patients with AEs, grade 3 AEs, serious AEs, AEs leading to discontinuation of drug, and AEs leading to death were generally well balanced between arms. Grade 2 neuropathy was reported in five (11%) LIFA patients versus two (4%) receiving PLD. There was a difference in LIFA versus PLD arms in AEs including abdominal pain (46% versus 28%), constipation (24% versus 38%), diarrhea (35% versus 19%), neutropenia (28% versus 17%), stomatitis (7% versus 30%), and palmar-plantar erythrodysesthesia syndrome (0% versus 26%) ( Table 2 ). Dose intensity was high for both arms (mean 6 SD: LIFA, 97.6 6 13.6%; PLD, 99.6% 6 18.4%). 
Pharmacokinetic and biomarker
The patient pharmacokinetic profiles were similar between the phases I and II studies across all three analytes [total antibody, antibody-conjugated MMAE (acMMAE), and unconjugated MMAE]. The PK properties of acMMAE and total antibody were generally similar (supplementary Table S1 , available at Annals of Oncology online), characterized by the relatively low V ss , long t 1/2 , and low CL, suggesting that the disposition of acMMAE appears to be driven by the antibody component. Minimal accumulation of acMMAE and total antibody was observed upon repeated administration of LIFA. There was relatively lower interindividual variability (<25%) in pharmacokinetic parameters at 2.4 mg/kg doses. Systemic exposure to unconjugated MMAE was consistently low across all patients and exhibited formation-rate limited kinetics. There was a trend in increased probability of tumor response with an increase in acMMAE exposure, with PLD pts: Figure 1 . Progression-free survival in intent-to-treat and NaPi2b-high populations.
similar trends evident in both the ITT and NaPi2b-high patients. Fifteen of 44 evaluable patients developed an ADA response to LIFA with no impact on pharmacokinetics, safety, or efficacy.
As the NaPi2b-high population based on IHC was unexpectedly high in this study (93%), we evaluated the association between response and NaPi2b protein level measured by H-score and transcript level (qRT-PCR) so as to increase the dynamic range of the measurement scale to allow for differentiation. Interestingly, there appeared to be a consistent trend between NaPi2b expression and efficacy (supplementary Figure S3 , available at Annals of Oncology online). In patients with NaPi2b Hscores higher than median, the objective response rate (ORR) in patients treated with LIFA was 44% versus 8% with PLD (95% CI, 6% to 67%; P ¼ 0.015), and the PFS HR was 0.47 for LIFA versus PLD. In patients with NaPi2b qRT-PCR values higher than median, the ORR in patients treated with LIFA was 50% versus 6% with PLD (95% CI, 16% to 72%; P ¼ 0.008), and the PFS HR was 0.54 for LIFA versus PLD.
Evaluation of CA-125 and HE4 biomarkers showed significant differences between treatment arms. The LIFA arm demonstrated a higher proportion of patients with 50% decline in CA-125 (LIFA 57% versus 24% PLD; P ¼ 0.004) and HE4 (LIFA 41% versus 12% PLD; P ¼ 0.005) (supplementary Figures S4 and S5 , available at Annals of Oncology online).
Discussion
ADCs represent a new approach of conferring selectivity to the delivery of highly potent cytotoxic agents. This is the first randomized phase II study to compare an MMAE in an ADC format to SOC chemotherapy in PROC patients. While a higher overall response rate was observed in patients receiving LIFA versus PLD, this did not translate to a statistically significant improvement in the primary end point of PFS in patients receiving LIFA. This study highlights that caution should be exercised when using response rate as the only metric of activity to move ADC programs into phase II trials. Overall, LIFA Q3W at 2.4 mg/ kg was well tolerated, and frequency and severity of AEs were similar between the two arms. The pharmacokinetic profiles for patients were similar between the phase I studies [20, 21] and this phase II study across all three analytes.
In the phase I study, preliminary data indicated a nonstatistically significant association between high H-scores and improved depth of response. In the phase II study, the majority of patients exhibited strong (2þ/3þ) NaPi2b expression, so that differentiation by standard IHC scoring could not be achieved. However, the use of either H-scores or qRT-PCR evaluation of NaPi2b expression established a greater dynamic range, and a trend towards increased activity and clinical benefit with increased NaPi2b expression could be observed by ORR and PFS HR. The expression of NaPi2b does not appear to change over time or with standard of care treatments in OC (data on file). These results support further exploration to determine how NaPi2b expression levels could be measured and utilized to best predict clinical benefit from LIFA.
The relationship between antitumor activity and changes in circulating CA-125 and HE4 levels was also evaluated. For patients with >50% decline in CA-125 or HE4, there were significant differences in outcome on the LIFA arm versus PLD. Thus, in this patient population, circulating CA-125 and HE4 may be surrogates for clinical response and may potentially predict durability of response, deserving further attention and validation for novel clinical applications. In addition to LIFA, ADCs directed against various targets are under investigation. Recently, a phase I trial of mirvetuximab soravtansine (IMGN853) described an overall response rate of 26% in all evaluable patients [22] , and that agent is being further developed in phase III trials. The experience with LIFA in this trial suggests that both response rate and DoR will be important factors in evaluating the activity of ADCs in OC. Although this phase II study confirmed findings from earlier studies of LIFA with an overall similar response rate in PROC [14] , this did not result in significantly extended PFS.
As a phase II trial that was designed to detect large improvements in PFS, it is possible that the observed PFS difference of 5.3 months in the LIFA arm and 3.1 months in the PLD months does reflect a very modest PFS improvement with LIFA that this trial was not powered to be able to detect. Even so, it is surprising that more than doubling the overall response rate would not result in a greater PFS difference [23] . As postprogression samples were not available, the mechanisms of resistance to LIFA remain unclear. However, one possibility is downregulation of the ADC target; while NaPi2b is highly expressed in 90% of OCs, it is not clear how vital it is to continued survival of the OC cell. It may be that targets that are critical to OC cell survival may result in higher durability of response to ADC-class therapies.
This study was hypothesis generating and was designed to detect only a large benefit of LIFA monotherapy. As the first randomized phase II trial to evaluate ADC format of a potent drug for PROC patients, this study confirms that ADCs can have significant clinical activity in PROC, with improved ORR compared with PLD, and an improvement in PFS although statistically nonsignificant in this small trial. However, this study also highlights that ORR alone may not translate to durable responses with ADCs, and that careful target selection, evaluation of target expression thresholds, response rate, and duration of response may all be important to the future development of antibodydirected cytotoxics in OC.
